🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

An U.S. FDA ODAC will be held May 20th to discuss the potential approval for Dara in smoldering myeloma #mmsm Very good points made in the discussion 👇 ➡️ fda.gov/media/186527/d… Few important observations summarised here🧵

Join leading #myeloma experts Drs. Dr. Amrita Krishnan & Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 for a free webinar exploring how bispecific antibodies work, their benefits, side effects, & what patients can expect during treatment. 📅 Wed, May 28 ⏰ 12 PM ET/9 AM PT 🔗 Register now: ow.ly/9TjC50VQlr5

Bispecific antibodies offer new hope for relapsed/refractory myeloma. In this new white paper, IMF NLB nurses share how they manage serious side effects, support care transitions, & empower patients to advocate for these promising new treatments. imf-d8-prod.s3.us-west-1.wasabisys.com/2025-03/NLB_Bi… #IMFNLB

Anil Makam Vincent Rajkumar Can’t agree more! A busy day in clinic never creates burnout (like the way a busy day on zoom meetings do)!

Congratulations Alexis LeVee, MD on your persistence and determination,and many more to come… looking forward to the scientific contributions

#ASCO25 Top myeloma abstracts #mmsm Here I provide my list of the 7 most exciting abstracts to watch for in the field of plasma cell disorders Looking for a productive meeting ASCO 🧵

MIDAS: IsaKRd followed by MRD driven treatment. MRD negative patients randomized to ASCT or more IsaKRd. MRD positive patients randomized to single vs tandem ASCT. - MRD < 10^-6 similar between ASCT and IsaKRd (84% vs 86%) among mrd negative patients pre-randomization - MRD <

1/ Another exciting year for myeloma #MMsm research! (IMROZ & BENEFIT last year seem like ages ago...) I'll miss #ASCO25 and #EHA2025 on paternity leave, but here are my top 10 #MMsm abstracts spanning CD38, BCMA, GPRC5D, and more... Thanks Mike Thompson, MD, PhD, FASCO as always for compiling!

Cancer Institute (W.I.A) Adyar Chennai. youtube.com/watch?v=sPJc1N…

Our recent publication looking at the genomic profile of Extramedullary Multiple Myeloma, a difficult to treat entity, with an urgent need for novel therapies. ⁦Mayo Myeloma⁩ ⁦Shaji Kumar⁩ ⁦Vincent Rajkumar⁩ ashpublications.org/bloodadvances/…

Thrilled that Dr. Saad Usmani Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 Chair of the myeloma program Memorial Sloan Kettering Cancer Center will receive the Giants of Cancer Care Award for Myeloma OncLive.com tomorrow. #ASCO25 Congrats dear friend! Best wishes on behalf of all our myeloma colleagues. Cheers!

Planning your #ASCO2025 schedule? Join me in the ASCO Trainee and Early Career Lounge as I moderate “Research 101: Identifying a Research Question & Deciding on a Study Design” with a fantastic panel! Neelima Denduluri Cassadie Moravek Alison Schram Govind Warrier MD, MPH Jasmin Hundal, M.D., DipABLM, M.S., M.P.H. ASCO TECAG

I’m excited to announce that we had a successful infusion for our first CAR-T patient today ! This is the first patient to receive CAR-T in the California Central Valley. I cannot thank our amazing team enough for their hard work which made this all possible. #UCSFFresno

How awesome! Looking forward to seeing Alexis LeVee, MD moderate a terrific session with dear friend Neelima Denduluri on "Research 101" just after Nazli Dizman moderates a session with me & another dear friend Edward S. Kim, MD, MBA, FACP, FASCO! Proud to see so many City of Hope colleagues (past & present) on the

All of this is also true of industry clinical development randomized trials, but due to adequate funding, fewer people with veto power, and international accrual reach the time element is considerably shortened. But the impact element remains, and is not in anyone’s hands. We

Myeloma / Plasma Cell Dyscrasia *DRAFT*~ #ASCO25Top10 (or so) #mmsm #mmMRD #ASCO25 - Mike Thompson, MD, PhD, FASCO - Update: 5/31/25 - cc Surviving Myeloma - Samer Al Hadidi, MD,MS,FACP Daniel Auclair Rahul Banerjee, MD, FACP Shaji Kumar Ben Derman Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 Keith Stockerl-Goldstein, MD 😷 @MyelomaTeacher - Cindy Chmielewski

He is on a great trajectory investigating metabolic causes of MGUS--> Smoldering MM --> MM

We need to streamline the process. My ECOG study is consistent with this timeline. I also just finished a call this Friday again, to harmonize the protocol. One of the most urgent needs is to expedite approved concepts through the system I really thank leaders Vincent Rajkumar

Good morning all. After yesterday's excitement about the CHALLENGE exercise trial, here is my critical appraisal on Sensible Medicine #ASCO25

In light of the CARTITUDE-1 trial outcome, I am grateful to BlackDoctor for writing this article about my myeloma journey! I would not call it beating... but I have survived almost 30 years with a cancer that is yet to be cured! "How I Beat a Deadly Cancer Nobody